Multiple myeloma risk linked to DNA damage response genes.

IF 47.8 1区 医学 Q1 HEMATOLOGY
Michael Conry,Irina Ostrovnaya,Yelena Kemel,Saloni Sinha,Linda B Baughn,Brian Avery,Kylee Maclachlan,Victoria Groner,Lauren Banaszak,Aaron Norman,Nicholas J Boddicker,Alyssa Clay-Gilmour,Shaji Kumar,Ellen Kim,Sita Dandiker,Mitul Waghmare,Susan Slager,Douglas W Sborov,Judy Garber,Elizabeth E Brown,Michelle Hildebrandt,Parameshwaran Hari,Nicola Camp,Celine Vachon,Saad Usmani,Kenneth Offit,Vijai Joseph
{"title":"Multiple myeloma risk linked to DNA damage response genes.","authors":"Michael Conry,Irina Ostrovnaya,Yelena Kemel,Saloni Sinha,Linda B Baughn,Brian Avery,Kylee Maclachlan,Victoria Groner,Lauren Banaszak,Aaron Norman,Nicholas J Boddicker,Alyssa Clay-Gilmour,Shaji Kumar,Ellen Kim,Sita Dandiker,Mitul Waghmare,Susan Slager,Douglas W Sborov,Judy Garber,Elizabeth E Brown,Michelle Hildebrandt,Parameshwaran Hari,Nicola Camp,Celine Vachon,Saad Usmani,Kenneth Offit,Vijai Joseph","doi":"10.1186/s13045-025-01776-1","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nDNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM).\r\n\r\nMETHODS\r\nHerein, we analyzed disease associations of pathogenic variations in nine putative candidate genes using 3 446 MM cases and 323 233 cancer-free controls.\r\n\r\nRESULTS\r\nIncreased MM risk was found to be associated with inherited rare pathogenic mutations in TP53, ATM, CHEK2, KDM1A, and ARID1A, with an enrichment of these variants among individuals with early onset or family history of MM. Individuals with TP53 or ATM germline mutations are also likely to have worse overall survival.\r\n\r\nCONCLUSIONS\r\nOur results suggest expansion of the phenotypic spectrum of some of these DDRG to include MM. The identification of these germline predisposition genes opens the avenue for targeted screening of higher risk individuals especially those with young-onset or a family history of plasma cell gammopathies.","PeriodicalId":16023,"journal":{"name":"Journal of Hematology & Oncology","volume":"32 1","pages":""},"PeriodicalIF":47.8000,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hematology & Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13045-025-01776-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND DNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM). METHODS Herein, we analyzed disease associations of pathogenic variations in nine putative candidate genes using 3 446 MM cases and 323 233 cancer-free controls. RESULTS Increased MM risk was found to be associated with inherited rare pathogenic mutations in TP53, ATM, CHEK2, KDM1A, and ARID1A, with an enrichment of these variants among individuals with early onset or family history of MM. Individuals with TP53 or ATM germline mutations are also likely to have worse overall survival. CONCLUSIONS Our results suggest expansion of the phenotypic spectrum of some of these DDRG to include MM. The identification of these germline predisposition genes opens the avenue for targeted screening of higher risk individuals especially those with young-onset or a family history of plasma cell gammopathies.
多发性骨髓瘤风险与DNA损伤反应基因有关。
dna损伤反应基因(DDRG)与多种癌症有关,既是易感危险因素,也是侵袭性的生物标志物,但在多发性骨髓瘤(MM)中尚未得到充分研究。方法采用3 446例MM病例和323 233例无癌对照,分析9个候选基因的致病变异与疾病的相关性。结果发现MM风险增加与TP53、ATM、CHEK2、KDM1A和ARID1A的遗传性罕见致病性突变有关,这些变异在早期发病或有MM家族史的个体中富集。携带TP53或ATM种系突变的个体也可能有较差的总生存率。结论研究结果表明,部分DDRG的表型谱扩展到包括MM。这些种系易感基因的鉴定为有针对性地筛查高风险个体,特别是那些年轻发病或有浆细胞γ病家族史的个体开辟了道路。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
48.10
自引率
2.10%
发文量
169
审稿时长
6-12 weeks
期刊介绍: The Journal of Hematology & Oncology, an open-access journal, publishes high-quality research covering all aspects of hematology and oncology, including reviews and research highlights on "hot topics" by leading experts. Given the close relationship and rapid evolution of hematology and oncology, the journal aims to meet the demand for a dedicated platform for publishing discoveries from both fields. It serves as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, hematologists, and oncologists in an open-access format. With a rapid turnaround time from submission to publication, the journal facilitates real-time sharing of knowledge and new successes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书